vh4011499
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 27, 2022 (NCT05393271)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06724640 | Phase 1 | Dec 16, 2024 | ViiV Healthcare |
| NCT06368986 | Phase 1 | Apr 17, 2024 | ViiV Healthcare |
| NCT06039579 | Phase 2 | Oct 25, 2023 | ViiV Healthcare |
| NCT06012136 | Phase 1 | Aug 24, 2023 | ViiV Healthcare |
| NCT05393271 | Phase 1 | May 27, 2022 | ViiV Healthcare |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ViiV Healthcare | For profit | 5 | 5 | 2 | 2022 |
1 organizations
Page 1 / 1